Webcast and Conference Call To be Held Thursday, May 9th, 2024, 8:30 am ETNEW YORK, May 02, 2024 (GLOBE NEWSWIRE)…
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on…
First long-term data presentation from Parts 1 and 2 of the Phase 1 clinical trial of sudocetaxel zendusortide in solid…
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…
- Presented cardiac magnetic resonance (CMR) imaging evidence consistent with clinical improvement observed in patients with transthyretin amyloid cardiomyopathy (ATTR-CM)…
VANCOUVER, BC / ACCESSWIRE / May 2, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a clinical stage…
LUND, SWEDEN / ACCESSWIRE / May 2, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Positive start to an important yearJANUARY - MARCH…
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness,…
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- Continued expansion of IP portfolio related to RNA delivery Treatment of rheumatoid…
- The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and…